|
1
|
Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, et al: Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 89 (Suppl 1):S173–S182. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Oates TW, Graves DT and Cochran DL: Clinical, radiographic and biochemical assessment of IL-1/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis. J Clin Periodontol. 29:137–143. 2002.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jandinski JJ, Stashenko P, Feder LS, Leung CC, Peros WJ, Rynar JE and Deasy MJ: Localization of interleukin-1 beta in human periodontal tissue. J Periodontol. 62:36–43. 1991.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kinane DF, Winstanley FP, Adonogianaki E and Moughal NA: Bioassay of interleukin 1 (IL-1) in human gingival crevicular fluid during experimental gingivitis. Arch Oral Biol. 37:153–156. 1992.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kornman KS, Crane A, Wang HY, di Giovine FS, Newman MG, Pirk FW, Wilson TG Jr, Higginbottom FL and Duff GW: The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol. 24:72–77. 1997.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lopez-Castejon G and Brough D: Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 22:189–195. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Marchesan JT, Girnary MS, Moss K, Monaghan ET, Egnatz GJ, Jiao Y, Zhang S, Beck J and Swanson KV: Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics. Periodontol 2000. 82:93–114. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pettersson M, Kelk P, Belibasakis GN, Bylund D, Molin Thorén M and Johansson A: Titanium ions form particles that activate and execute interleukin-1β release from lipopolysaccharide-primed macrophages. J Periodontal Res. 52:21–32. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Martinon F, Burns K and Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 10:417–426. 2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bostanci N, Emingil G, Saygan B, Turkoglu O, Atilla G, Curtis MA and Belibasakis GN: Expression and regulation of the NALP3 inflammasome complex in periodontal diseases. Clin Exp Immunol. 157:415–422. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Park E, Na HS, Song YR, Shin SY, Kim YM and Chung J: Activation of NLRP3 and AIM2 inflammasomes by Porphyromonas gingivalis infection. Infect Immun. 82:112–123. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Aral K, Berdeli E, Cooper PR, Milward MR, Kapila Y, Karadede Ünal B, Aral CA and Berdeli A: Differential expression of inflammasome regulatory transcripts in periodontal disease. J Periodontol. 91:606–616. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shibata K: Historical aspects of studies on roles of the inflammasome in the pathogenesis of periodontal diseases. Mol Oral Microbiol. 33:203–211. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Aral K, Milward MR, Kapila Y, Berdeli A and Cooper PR: Inflammasomes and their regulation in periodontal disease: A review. J Periodontal Res. 55:473–487. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Strowig T, Henao-Mejia J, Elinav E and Flavell R: Inflammasomes in health and disease. Nature. 481:278–286. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zahid A, Li B, Kombe AJK, Jin T and Tao J: Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 10(2538)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rathinam VA and Fitzgerald KA: Inflammasome complexes: Emerging mechanisms and effector functions. Cell. 165:792–800. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Guo H, Callaway JB and Ting JP: Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat Med. 21:677–687. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhang Y, Dong Z and Song W: NLRP3 inflammasome as a novel therapeutic target for Alzheimer's disease. Signal Transduct Target Ther. 5(37)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Delaleu N and Bickel M: Interleukin-1 beta and interleukin-18: Regulation and activity in local inflammation. Periodontol 2000. 35:42–52. 2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kim S, Park MH, Song YR, Na HS and Chung J: Aggregatibacter actinomycetemcomitans-induced AIM2 inflammasome activation is suppressed by xylitol in differentiated THP-1 macrophages. J Periodontol. 87:e116–e126. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T and Ando T: Regulation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated periodontal disease. Inflamm Res. 66:59–65. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Isaza-Guzmán DM, Medina-Piedrahíta VM, Gutiérrez-Henao C and Tobón-Arroyave SI: Salivary Levels of NLRP3 Inflammasome-Related Proteins as Potential Biomarkers of Periodontal Clinical Status. J Periodontol. 88:1329–1338. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Higuchi K, Ziamuddin SM, Yamashita Y, Ozaki Y and Yoshimura A: Initial periodontal treatment affects nucleotide-binding domain leucine-rich repeat-containing protein 3 inflammasome priming in peripheral blood mononuclear cells. Arch Oral Biol. 110(104625)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T and Ando T: Activation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated atherosclerosis. Pathog Dis. 73(ftv011)2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD and Latz E: Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 17(688)2018.PubMed/NCBI View Article : Google Scholar : Erratum for: Nat Rev Drug Discov 17: 588-606, 2018.
|
|
27
|
Van Dyke TE: Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med. 58:21–36. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chapple IL: Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol. 24:287–296. 1997.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Brock GR, Butterworth CJ, Matthews JB and Chapple IL: Local and systemic total antioxidant capacity in periodontitis and health. J Clin Periodontol. 31:515–521. 2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
So AK and Martinon F: Inflammation in gout: Mechanisms and therapeutic targets. Nat Rev Rheumatol. 13:639–647. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Favus MJ and Coe FL: The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. Scand J Urol Nephrol Suppl. 53:265–271. 1980.PubMed/NCBI
|
|
32
|
Becker MA, MacDonald PA, Hunt BJ and Jackson RL: Diabetes and gout: Efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 15:1049–1055. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Szeto HH: First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 171:2029–2050. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lynch DR and Farmer G: Mitochondrial and metabolic dysfunction in Friedreich ataxia: Update on pathophysiological relevance and clinical interventions. Neuronal Signal. 5(NS20200093)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Mehmel M, Jovanović N and Spitz U: Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. Nutrients. 12(1616)2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, O'Connor C, Goldstein S, Udelson JE and Sabbah HN: Novel mitochondria-targeting peptide in heart failure treatment: A randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 10(e004389)2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Cornelis S, Kersse K, Festjens N, Lamkanfi M and Vandenabeele P: Inflammatory caspases: Targets for novel therapies. Curr Pharm Des. 13:367–385. 2007.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ and Gores GJ: The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 35:953–966. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, Decker C, Charifson P, Weber P, Germann UA, et al: (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 321:509–516. 2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
de Torre-Minguela C, Mesa Del Castillo P and Pelegrín P: The NLRP3 and pyrin inflammasomes: Implications in the pathophysiology of autoinflammatory diseases. Front Immunol. 8(43)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
MacKenzie SH, Schipper JL and Clark AC: The potential for caspases in drug discovery. Curr Opin Drug Discov Devel. 13:568–576. 2010.PubMed/NCBI
|
|
42
|
Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A and Morita R: Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. 6(7360)2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pokhrel NK, Kim YG, Kim HJ, Kim HJ, Lee JH, Choi SY, Kwon TG, Lee HJ, Kim JY and Lee Y: A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption. J Periodontol. 90:546–554. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T and Akira S: Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 14:454–460. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Aral CA, Aral K, Yay A, Özçoban Ö, Berdeli A and Saraymen R: Effects of colchicine on gingival inflammation, apoptosis, and alveolar bone loss in experimental periodontitis. J Periodontol. 89:577–585. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Cheng R, Wu Z, Li M, Shao M and Hu T: Interleukin-1β is a potential therapeutic target for periodontitis: A narrative review. Int J Oral Sci. 12(2)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Yoshinari N, Kawase H, Mitani A, Ito M, Sugiishi S, Matsuoka M, Shirozu N, Ishihara Y, Bito B, Hiraga M, et al: Effects of scaling and root planing on the amounts of interleukin-1 and interleukin-1 receptor antagonist and the mRNA expression of interleukin-1beta in gingival crevicular fluid and gingival tissues. J Periodontal Res. 39:158–167. 2004.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mistry P, Reid J, Pouliquen I, McHugh S, Abberley L, DeWall S, Taylor A, Tong X, Rocha Del Cura M and McKie E: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects. Int J Clin Pharmacol Ther. 52:867–879. 2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I, Farlik M, Decker T, Du Pasquier RA, Romero P, et al: Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 34:213–223. 2011.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Rathinam VA, Vanaja SK and Fitzgerald KA: Regulation of inflammasome signaling. Nat Immunol. 13:333–342. 2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Hu Y, Mao K, Zeng Y, Chen S, Tao Z, Yang C, Sun S, Wu X, Meng G and Sun B: Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J Immunol. 185:7699–7705. 2010.PubMed/NCBI View Article : Google Scholar
|
